BioCentury | Nov 8, 2019
Clinical News

Cirius plots path forward for NASH candidate despite missed primary in Phase IIb

...enough likelihood of Phase III success to move forward with a pivotal study of the mTOT...
...Renaissance Venture Capital Fund and Hopen Life Science Ventures (see “More NASH Cash” ). Targets: mTOT...
...target of thiazolidinedione; PPARγ - Peroxisome proliferation activated receptor γ Paul Bonanos, Associate Editor MSDC-0602, MSDC-0602K Cirius Therapeutics Inc. Mitochondrial target of thiazolidinediones (mTOT) non-alcoholic...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

...a metabolic disease play co-founded by Colca, showed TZDs also bind two targets in the mitochondrial target of thiazolidinediones (mTOT)...
...1 (MPC1; BRP44L) and MPC2 (BRP44) -- and treat liver fibrosis through inhibition of the mTOT...
...Japan References Colca, J., et al. “Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--Relationship...
BioCentury | Nov 30, 2017
Translation in Brief

Two faces of FOXO1

...they think will not induce weight gain. Metabolic Solutions Development Co. has two modulators of mitochondrial target of thiazolidinediones (mTOT)...
...Staff Writer methazolamide MSDC-0160 MSDC-0602 PN2034 AstraZeneca plc Columbia University Metabolic Solutions Development Co. Verva Pharmaceuticals Ltd. Wellstat Therapeutics Corp. Forkhead box O1 (FOXO1) Glucokinase (GCK) (GK) Mitochondrial target of thiazolidinediones (mTOT) Peroxisome...
BioCentury | Apr 14, 2017
Finance

More NASH cash

...the Phase IIb EMMINENCE trial of MSDC-0602K , a next-generation insulin sensitizer that inhibits the mitochondrial target of thiazolidinediones (mTOT)...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...NASDAQ:ECYT) EC0371 mTOR inhibitor PKD Preclinical Metabolic Solutions Development Co. MSDC-0602 Mitochondrial target of thiazolidinedione (mTOT...
Items per page:
1 - 5 of 5